{"id":"doi:10.1016/j.pcad.2025.05.008","kind":"article","title":"Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience","authors":["Bosco G","Di Giacomo Barbagallo F","Di Marco M","Scilletta S","Miano N","Esposto S","Pennisi G","Prezzavento S","Gallo A","De Francesco EM","Malaguarnera R","Di Pino A","Purrello F","Piro S","Scicali R"],"author_count":15,"year":2025,"published":"2025-05-26","venue":"Progress in cardiovascular diseases","cited_by":26,"doi":"10.1016/j.pcad.2025.05.008","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.pcad.2025.05.008","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.pcad.2025.05.008","updated":null,"pmid":"40436259","pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"Background and aims Familial hypercholesterolemia (FH) is characterized by elevated LDL-C and an increased risk of premature cardiovascular events. Inclisiran is a small interfering RNA that inhibits hepatic PCSK9 synthesis and promotes LDL-C clearance by enhancing LDLR expression on hepatocytes. This study aimed to evaluate the efficacy of six-months add-on inclisiran on lipid profile and PWV in FH; furthermore, we investigated the association between LDL-C reduction and PWV variation. Methods This prospective observational study involved 78 genetically confirmed FH subjects with an LDL-C off-target despite high-intensity statins plus ezetimibe. All subjects obtained biochemical analysis and PWV evaluation at baseline and after six months add-on inclisiran. Results After six months add-on inclisiran, 41 % of subjects achieved LDL-C targets. Significant reductions of LDL-C (-41.5 %, p < 0.001), ApoB (-33.7 %, p < 0.01), Non-HDL-C (-35.9 %, p < 0.001), and Lp(a) (-18 %, p < 0.01) were observed, while PWV improved by 14.4 % (p < 0.001). In a secondary analysis, the Primary prevention group showed a higher prevalence of subjects on LDL-C target than the Secondary prevention group (59 % vs 23.1 %, p < 0.001). Both groups exhibited significant improvements of lipid profile and PWV (Δ - 14.1 %, p < 0.01 and Δ - 14.6 %, p < 0.001, respectively). Linear regression showed a significant association between ΔPWV and ΔLDL-C in the whole study population as well as in the Primary and Secondary prevention groups (p for all <0.001). Conclusion Inclisiran significantly improved lipid profile and PWV in FH subjects. ΔPWV was significantly associated with ΔLDL-C.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience\" by Bosco G, Di Giacomo Barbagallo F, Di Marco M et al., https://doi.org/10.1016/j.pcad.2025.05.008, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}